Are we progressing in prostate cancer management?

doi:10.1016/j.ajur.2020.09.001

Asian Journal of Urology, 2021, 8 (2): 241-242 doi: 10.1016/j.ajur.2020.09.001

Coummentary

Current Issue | Archive | Adv Search

Are we progressing in prostate cancer management?

Hiten RH. Patel^a,*(

),Reena Patel^b

^a Department of Urology, University of Rochester Medical & Dental School, NY, USA
^b St George’s University of London Medical School, London, United Kingdom

Abstract
Related Citation (0)

[1]	Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68:394e424.
[2]	Lawrence M, Porter L, Clouston D, Murphy D, Frydenberg M, Taylor R, et al. Knowing what’s growing: why ductal and intraductal prostate cancer matter. Sci Transl Med 2020; 12:eaaz0152. https://doi.org/10.1126/scitranslmed.aaz0152.
[3]	Meeks J, Zhao L, Cashy J, Kundu S. Incidence and outcomes of ductal carcinoma of the prostate in the USA: analysis of data from the Surveillance, Epidemiology, and End Results program. BJU Int 2011; 109:831e4.
[4]	Wu Y, Chen S, Wang S, Li X, Cai H, Lin Y, et al. Prognostic values of clinicopathological characteristics and survival outcomes in prostate infiltrating ductal carcinoma: a populationbased study. Oncotarget 2017; 8:29048e55.
[5]	Liu M, Jin K, Qiu S, Xu P, Zhang M, Cai W, et al. Oncological outcomes of patients with ductal adenocarcinoma of the prostate receiving radical prostatectomy or radiotherapy. Asian J Urol 2020; 8:227e34.
[6]	Trinh V, Sirois J, Benzerdjeb N, Mansoori B, Grosset A, Albadine R, et al. The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancerspecific survival. Prostate 2018; 78:697e706.
[7]	Montironi R, Zhou M, Magi-Galluzzi C, Epstein J. Features and prognostic significance of intraductal carcinoma of the prostate. Eur Urol Oncol 2018; 1:21e8.
[8]	Mottet N, van den Bergh R, Briers E, Cornford P, De Santis M, Fanti S, et al. EAU-ESTRO-ESUR-SIOG guidelines on prostate cancer. Arnhem, The Netherlands: European Association of Urology [accessed 4th February 2021]. https://uroweb.org/guideline/prostate-cancer/.
[9]	Gillard M, Lack J, Pontier A, Gandla D, Hatcher D, Sowalsky A, et al. Integrative genomic analysis of coincident cancer foci implicates CTNNB1 and PTEN alterations in ductal prostate cancer. Eur Urol Focus 2019; 5:433e42.
[10]	Jamaspishvili T, Berman D, Ross A, Scher H, De Marzo A, Squire J, et al. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol 2018; 15:222e34.